hVIVO reports H1 revenue decline, orderbook more than doubles

hVIVO reported H1 2026 revenue of £16.3 million, down 33% year-on-year, while adjusted EBITDA loss widened to £4.5 million from £3.0 million and cash declined to £13.0 million. Offsetting the weak first half, its signed-contract orderbook more than doubled to £65 million, and management expects H2 revenue to be roughly twice H1 revenue, positive H2 adjusted EBITDA, and approximately £47 million of full-year revenue. The August acquisition of CRS Berlin adds Phase I/II dermatology and women's-health capabilities, while the CFO will retire and be replaced on an interim basis by director Richard Cotton.

Analysis

HVO is transitioning from a capacity-utilization story to an execution-and-cash-conversion story. The contracted backlog provides unusually strong forward visibility for a small clinical-services company, but it does not eliminate working-capital risk: trial revenue is milestone-based, while staff, facilities and trial-participant costs are incurred ahead of collections. The key near-term question is whether the guided second-half inflection produces cash generation rather than merely adjusted-EBITDA improvement.

CRS Berlin broadens HVO beyond respiratory human-challenge studies and could raise cross-selling value with repeat sponsors, but it also introduces integration risk precisely as management is attempting a sharp margin recovery. The CFO transition is a modest governance overhang; markets will want evidence that revenue recognition, earnout accounting and integration costs are conservatively managed. Given AIM liquidity, a guidance miss could generate an outsized drawdown even if the multi-year strategic thesis remains intact.

Consensus may underappreciate the strategic value of a pivotal human-challenge trial: successful execution could validate the model for later-stage programs and improve pricing power versus conventional CROs. Conversely, this is not equivalent to biotech drug-development optionality; HVO's economics remain dependent on sponsor budgets, site capacity and operational delivery. The appropriate rerating catalyst is therefore demonstrated H2 cash conversion and 2027 backlog replenishment, not the headline size of signed contracts alone.

Key Decisions for Investors

• Watch HVO rather than chase the initial guidance-driven move; initiate only after the next trading update confirms H2 revenue run-rate, positive adjusted EBITDA and no material deterioration in net cash. A 6-12 month position is justified if these metrics validate operating leverage; absent cash-flow disclosure, size as a small-cap liquidity-risk position.
• Use the H2 results as the binary catalyst: add on evidence that cash is stable-to-higher despite the ramp and CRS integration; reduce or avoid if receivables expand materially, cash declines faster than the implied EBITDA loss, or FY EBITDA guidance is cut.
• For relative exposure, prefer HVO over early-stage therapeutics with comparable clinical-trial headlines: HVO offers contracted-service revenue rather than trial-readout risk. The trade fails if sponsor concentration increases, repeat-client activity weakens, or human-challenge demand proves cyclical under tighter biotech funding conditions.
• Do not infer any signal for APP or SMCI from this item; their inclusion is promotional and has no operational or valuation linkage to HVO.